Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on advancing innovative medicines, has several important catalysts on the horizon in 2025 that could shape its long-term trajectory.
The company's lead product candidates, Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, are making significant progress, with pivotal milestones expected to drive value for the company.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com